Retatrutide — 30mg
Retatrutide is a novel triple-agonist research peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. It is currently under investigation in multiple Phase 3 clinical trials for its effects on metabolic pathways. This compound represents a significant area of active research in receptor pharmacology.
Satisfaction Guarantee: If your order arrives damaged or does not match the certified specification, we will replace it. No questions asked.
Specifications
- Sequence
- Triple agonist (GLP-1/GIP/Glucagon)
- Molecular Weight
- ~4,471 Da
- Quantity
- 30mg per vial
- Purity
- ≥98% (HPLC verified)
- Form
- Lyophilized powder
- Appearance
- White to off-white powder
- Storage
- -20°C recommended, protect from light
Certificate of Analysis
This product is supplied with a third-party certificate of analysis verifying ≥98% purity via HPLC.
Download COA (PDF)Research Applications
Retatrutide has been studied in preclinical and clinical research settings for its multi-receptor agonist activity. Published research includes investigations into metabolic signaling pathways, receptor binding affinity studies, and dose-response characterization across GLP-1, GIP, and glucagon receptor systems. Ongoing Phase 3 clinical trials (TRIUMPH program) are evaluating this compound across multiple research indications.
Key Published Research
- Jastreboff et al., NEJM 2023 — Phase 2 triple hormone receptor agonist trial
- Multiple TRIUMPH Phase 3 trial registrations — ClinicalTrials.gov
Storage & Handling
Store lyophilized powder at -20°C. Protect from light and moisture. Stable at room temperature during transit for up to 30 days. Once reconstituted for research use, store at 2-8°C and use within 30 days.
Other Compounds Researchers Also Order
Customer Feedback
“Third order from PSS. Purity is always on point and the COAs actually check out — sent one to Janoshik myself. Hard to find a source this consistent.”
Mike R.